Biotech Values

[si39]

Barrons
By Josh Nathan-Kazis
July 24, 2020 9:11 am ET

, Moderna played down the significance of the ruling.

“To the extent it is believed the PTAB erred in their decisions, Moderna may further pursue these matters,” the company said. “Moderna has invested in proprietary LNP delivery technology that we expect will allow us to deliver on our mission of creating a new generation of transformative medicines for patients. Moderna is not aware of any significant intellectual property impediments for any products we intend to commercialize, including mRNA-1273.”

https://www.genengnews.com/news/moderna-eyes-appeal-as-board-upholds-an-arbutus-lipid-nanoparticle-patent/
In a second statement issued today, Moderna said that it had improved upon the LNP technology covered by three Arbutus patents that included the one upheld yesterday by the PTAB: “Moderna’s continued development of its proprietary LNP formulation technology and manufacturing processes have advanced well beyond the technology described in these legacy Arbutus patents. Our improved proprietary LNP formula, used to manufacture mRNA-1273, is not covered by the Arbutus patents.”

Both statements concluded: “Moderna is not aware of any significant intellectual property impediments for any products we intend to commercialize, including mRNA-1273.”